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to result in any great changes, although in certain areas, price reductions can be 
expected. ConClusions: Some downward pressure on prices in other EU markets 
is likely as Croatia becomes a reference market for IRP, although this is likely to be 
limited in scope in the short term, with only particular products and therapeu-
tic groups affected. Over the longer term, as more markets add Croatia to their 
reference-pricing baskets, this pressure is likely to intensify.
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objeCtives: The Health (Pricing and Supply of Medical Goods) Act 2013 passed in 
June 2013 provides for generic substitution in Ireland. The aim of the study was to 
ascertain the views of the stakeholders i.e. patients, pharmacists and prescribers on 
generic substitution,prior to the Act’s introduction. Methods: Three stakeholder 
specific surveys were developed to assess knowledge of and attitudes to generic 
substitution. Convenience samples of health care professionals and patients were 
gathered until data saturation was achieved. Descriptive quantitative and qualita-
tive analysis was undertaken. Results: A total of 742 health care professionals 
and 330 patients responded. The study highlighted 4 areas where prescribers and 
pharmacists differed; (1) Prescribers ranked cost-savings as the most important 
information to impart to patients while pharmacists advocated therapeutic equiva-
lence as highest. (2) Pharmacists considered that more patients would be agreeable 
to generic substitution (52%) as compared to 41% of prescribers. (3) Prescribers 
considered that generic substitution would have a greater effect (25%) on patient 
care than pharmacists (14%). (4) 19% of prescribers supported generic substitution in 
all cases and 76% with some exceptions, compared to 16% and 84% for pharmacists 
respectively. More than 80% of patients were on between 1 and 8 medicines daily, 
and of these > 50% reported that they were on generic medicines. More than 80% 
would be happy with generic substitution, while more 75% of those interviewed 
considered generic drugs to contain the same drug, to be as effective and as safe 
as branded medicines. ConClusions: To prevent possible confusion and concern 
among patients it is important that health care professionals acquire the necessary 
tools and knowledge to manage transition into and rollout of this new system, so 
that they can work together to ensure the obvious benefits of the new system are 
maximised.
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objeCtives: Potentially inappropriate medication (PIM) in the elderly increases 
the risk of adverse drug reactions (ADR) and consequently has an impact on both 
patients’ quality of life and health care costs. In 2010, the PRISCUS list was published 
in Germany to identify PIM and to propose adequate substitution medication. The 
objective of the study was to assess both the prevalence and reimbursement of 
PIM in a German practice network applying the PRISCUS list. Moreover, costs for 
proposed surrogates were evaluated. Methods: Patients fulfilling the following 
criteria were included: (1) insured at the local health fund AOK Bavaria, (2) treated 
by physicians of the practice network, and (3) aged ≥ 65. Data was provided from 
AOK Bavaria and contained 214,177 anonymized prescriptions between Q1/2009 
and Q4/2011. Information included age, gender, date of prescription and ATC-Code. 
Since no information on dosage or package size was given, medication and its 
application duration were differentiated in acute and long-term medication by 
expert opinion. Costs were calculated by applying the concept of DDD. Results: 
On average, 16.0% of the patients received at least one PIM prescription each quarter. 
13,736 prescriptions were classified as PIM (6.4%; 68.7% to women). Out of these, 
psycholeptics such as Zopiclon (11.8%) and calcium antagonists such as Nifedipin 
(7.9%) were prescribed most frequently. Total costs of PIM-prescriptions were cal-
culated to be 446,430€ (mean 40,585€ per quarter; min. 32,869€ ; max. 50,024€ ). 
When assuming prescription of surrogates, costs varied between 267,990€ and 
935,826€ . ConClusions: PIM represents both a medical and economic burden to 
the German health care system. From an economic perspective, substitution of PIM 
may result in cost disadvantages. Thus, there is little economic incentive for health 
insurances to further promote the substitution of PIM. Future research should take 
a broader perspective and include costs of PIM-related ADR to fully evaluate the 
economic impact of PIM in the elderly.
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How doeS PreScriPtion of Generic druGS SPread out?: data mininG 
and ViSualization by uSinG PreScriPtion data form acute care 
HoSPitalS nationwide
Shimizu S.1, Ishikawa K.B.2, Ikeda S.3, Fushimi K.4
1Institue for Health Economics and Policy, minato-ku, Japan, 2National Cancer Center, Tokyo, 
Japan, 3International University of Health and Welfare, Ohtawara-City, Japan, 4Tokyo Medical and 
Dental University Graduate School of Medicine, bunkyo-ku, Tokyo, Japan
objeCtives: To clarify the spread with prescription of generic drugs and the shift 
from brand drug market by using nationwide administrative data. Methods: For 
the sample, out of 30 drugs seen as the parameter for generic drugs in France, 27 
have been selected after considering their availability in Japan. For those drugs 
unapproved in Japan, they were replaced by other drugs with the same effects, 
and anticancer agents as well as radio contrast agents were added. New drugs 
listed to National Health Insurance list around the same time were also included 
for comparison. Database was created by extracting the data of patients who were 
results. ConClusions: The current study extends the evaluation into Europe to 
confirm that as reimbursement decision makers continue to rigorously review new 
drug therapies, accurate, robust, peer-reviewed published and generalisable real-
world data will become particularly important for outcomes- or performance-based 
access schemes and health care budget management both in the US and Europe.
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objeCtives: To review the new drugs which were listed in the past on the Medical 
Fee Schedule of Japan, and to clarify the profile of the quasi value-based pricing 
in the Japan-style premium scheme. Methods: The information on pricing deci-
sions with premium was searched, extracted, and analyzed from the government 
documents open to public on the website of the Ministry of Health, Labour and 
Welfare in Japan. The four drug categories were focused due to data availability: 1) 
antihypertensive; 2) antidiabetic; 3) antibiotic; and 4) psychotropic, listed from April 
1998 through April 2013. The information relevant to the premium decision included 
listing dates, drug prices, premium categories, premium rates, and also clinical evi-
dence that could be associated with the premium decision. Results: Among total 
106 of new drugs, 27 have been identified with premium, whilst 79 with no premium. 
For each category, there existed 12 antihypertensive (single agent), 25 antidiabetic, 52 
antibiotic, 17 psychotropic. That is, the acquisition rate of premium for each category 
was 17%, 20%, 31% and 24%, respectively. The high proportion, 85%,of the rewarded 
premium categories was recognized in the category of “Usefulness II”, i.e., the 3rd 
ranked premium, while only one drug obtained the premium of innovativeness, the 
highest ranked premium. Regarding the benefit associated with the premium, both 
of clinical and humanistic outcomes seemed to be accepted for decision-making 
although the criteria for the decisions were not clearly indicated. ConClusions: 
The profile of the Japan-style premium scheme was clarified based on the survey 
over the new drugs listed in 1998 to 2013. The information extracted in our study 
will be useful for further investigations to improve the Japanese quasi value-based 
pricing methods.
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Sarría-Santamera A., Polo M., Gacía S.
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objeCtives: Spain has a decentralized health care systems with several levels of 
decision-making. After a drug is approved by the Spanish Agencia del Medicamento, 
regional committees (RC) conduct evaluate and assess those drugs for their use 
in ambulatory settings making recommendations to health professionals within 
its territory. The objective of this study is to analyze the structure and process of 
work of those RC. Methods: RC were contacted by phone and informed about 
this study. A web based questionnaire was ellabored including questions on: 1) 
General information of the RC; 2) Procedure of work of RC; and 3) Criteria used for 
the selection of medicines to asess and the procedures followed to. A link was sent 
by email to contact persons of the RC of the Spanish 17 Autonomous Comunities 
(AC). Results: To this date 10 RC (59%) have submitted their answers and 3 regions 
(18%) have responded indicating the absence of this type of structure or process in 
their region. These 3 regions, though, make recommendations usually conducting 
their own assessments or using assessments conducted by other regions. 7 RC 
have a normalized process of work (5 is open to the public). 8 RC have more than 8 
members. All RC evaluate medicines prescribed for outpatients purchased through 
pharmacies (5 of them exclusively), and 5 conduct also assessments of drugs used 
in hospitals. 9 RC use as comparator the standard treatment for a given indication. 
Economic evaluation is performed through budget impact (6 RC), cost-effectiveness 
(5 RC); and cost-minimization (2 RC). 6 RC make public their assessments through 
public web pages and 2 using electronic bullletins. ConClusions: Preliminary data 
indicate that the majority of Spanish regions conduct their own drug assessments, 
and most of them have established RC, whose structure and process of work show 
some variability and indicate certain degree of duplication.
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Melck B., Izmirlieva M., Ando G.
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objeCtives: To assess the implications of Croatia’s accession to the European Union 
for the pricing and reimbursement landscape both in Croatia and other EU member 
states, focusing on international reference pricing. Methods: Changes to Croatia’s 
laws governing drug pricing and reimbursement were examined in detail, in rela-
tion to their likely effects on drug prices in Croatia and in other EU member states 
through international reference pricing. The IHS International Reference Pricing 
Matrix was used to determine impact of Croatian prices on other markets likely 
to include Croatia in their reference pricing basket. Interviews were conducted 
with representatives of the pharmaceutical industry in Croatia, and regulators in 
Croatia and other EU member states, to gauge their views. Results: The exist-
ence of comparatively low prices of medicines in Croatia is likely to result in some 
downward pressure on pricing in countries which include all EU countries in the 
IRP basket of countries. However, this impact is not likely to be felt immediately, 
and only for the few therapeutic areas where Croatia’s prices are among the lowest 
in Europe. Changes to Croatia’s international reference pricing basket are unlikely 
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the 646 records found, 108 studies met the inclusion criteria (29 cost-effectiveness 
studies (CES) and 81 systematic reviews on effectiveness (SRE)). The majority of 
CES addressed adherence (55%), followed by inappropriate prescribing (31%) and 
prescribing errors (28%). No studies addressed the full medicines pathway. A simi-
lar picture emerged for SRE at 67%, 15 and 11 respectively. Among the 15 types of 
outcomes used in CES, the top three were clinical (31%) measures of adherence 
(21%) and quality-adjusted life years (17%). In SRE, hospitalisations (43%), measures 
of adherence (23%) and mortality (21%) were the most frequent. ConClusions: 
Interventions to improve suboptimal use of medicines tend to be specific to a par-
ticular aspect of the pathway and/or to a particular disease area. Little considera-
tion is made on how to improve medicines use in patients with co-morbidities and 
poly-medication. The medicines pathway is rarely examined holistically but in a 
fragmented manner, making it difficult to draw conclusions on which aspect of 
suboptimal use of medicines should be prioritised for investment.
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tHe effect of reduced or remoVed coPaymentS for PreScriPtion 
medicineS on adHerence – a SyStematic reView
Sinnott S.J., Sinnott C.M., Whelton H.
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objeCtives: To examine the effect of removal or reduction in prescription copay-
ments, in the absence of disease management plans, on adherence to prescription 
medications. Methods: Six electronic databases were systematically searched 
for relevant articles, along with hand searches of references in review articles and 
the included studies. Studies were included if they involved an intervention which 
reduced or removed copayments and if the outcome was objectively measured 
adherence. Study designs permitted were randomised controlled trials, time series 
analyses, controlled before/after studies and cohort studies. Studies were excluded 
if the intervention was part of a disease management plan. Study exclusion, data 
extraction and quality appraisal were carried out by two independent reviewers. 
Data were qualitatively synthesised. Results: Nine out of 40 studies were included. 
One study was an RCT; the remainder were all controlled before/after studies. 
There were 144,991 cases and 125,057 controls in this review. The mean age was 
54.39yrs and 55.21yrs for the cases and controls respectively. 44.79% of the cases 
were female, whereas 49.54% of the controls were female. Four studies analysed the 
effect of reduced copayment, 4 studies analysed the effect of a removed copayment 
and 1 study analysed both. Only one study received a strong quality assessment, 
one study was rated as moderate, and the remainder were rated as weak. Seven 
studies showed a significant improvement in adherence. Two studies did not show 
an improvement in adherence. ConClusions: This review concludes that there 
is some evidence of small increases in adherence on the removal or reduction of 
copayments. However, confounders and biases between the included studies were 
variable. Future studies should concentrate on establishing associations between 
reduced cost-sharing and clinical and economic outcomes.
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PreValence of PHySicianS cauSinG Potential druG interactionS in 
ambulatory care in Switzerland: a rePreSentatiVe national SurVey
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objeCtives: No representative data on the quality of drug prescription exist in 
Switzerland. We analysed potential drug interactions (PDI) in primary care based 
on prescription data from 2010 from three large health insurers. Methods: In our 
study population we identified based on the national drug formulary 494 drug-
drug interactions (DDI) classes. Of those, 41 were from drug interaction severity 
classes I (contraindicated) and II (potentially contraindicated) and classified as PDI. 
PDI were calculated for two indicators with different denominators, 1) the total 
number of DDI and 2) the total number of patients potentially exposed to a PDI. 
For each physician we calculated the probability that the number of caused PDI 
was unlikely (p-value between 0.05 and 0.01; ‘problematic prescription behaviour’) 
and very unlikely (p-value < 0.01; ‘likely problematic prescription behaviour’) to be 
explained by chance. Results: Of 3.13 million individuals 1.34% were exposed to 
at least one PDI; figures increased to 3.78% and 4.40% in females and males aged 
≥ 70 years. Of 20,710 physicians 42% caused at least one PDI. With DDI being the 
denominator 6.2% und 3.4% of general practitioners and 0.9% und 0.5% of specialists 
were classified with a ‘problematic’ and ‘likely problematic prescription behaviour’. 
With the patient population being the denominator between 0.96% and 6.22% of 
physicians from all specialty groups had caused a PDI that was classified as ‘likely 
problematic’ (p-value < 0.01). When combining both indicators 457 of 20‘720 physi-
cians (2.2%) had a prescription behaviour causing a PDI that in comparison to peers 
was highly unlikely to be explained by chance (p-value < 0.01). ConClusions: A 
total of 2.2% of physicians in primary care prescribe during one year at least one 
drug combination that is classified as PDI. A linkage to other data sources would 
be needed to further classify PDI that put patients at serious risk for adverse drug 
reactions.
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objeCtives: The study focus was to evaluate and compare the prescriptions for 
the encountered potential drug-drug interactions (pDDIs) and their different levels 
on the basis of onset, severity and documentation status, in a tertiary care hos-
pital and community pharmacies in Bahawalpur, Pakistan. Methods: Total 800 
prescriptions, 400 from a tertiary care teaching hospital and 400 from community 
pharmacies, fulfilling inclusion criteria were collected thrice a week during a period 
of three months and were analyzed for potential drug-drug interactions using dug 
digest database, drug interaction checker of www.drugs.com and reference text 
prescribed those drugs from DPC/PDPS data collected between 1st April 2010 and 
31st March 2012 at 1139 of acute care hospitals in Japan. Hospitals were classified 
into five categories (university, private, publi, social insurance group, and others). 
SQL Server 2008 R2 was used for data handling, R for data analysis, and ArcGIS for 
statistical analysis of geography. Results: Generic drugs were least used amongst 
almost all types of drugs in university hospital and social insurance group. For 
prescription of generic drugs, private hospital was the most proactive, followed 
by public hospital. It was revealed, thorough comparison between 20% of medical 
care institutions that are the most proactive towards introduction of generic drugs 
and 20% of the least proactive, that the shifting progress was slower in bigger size 
medical care institutions. ConClusions: This study indicated that for effective 
promotion of generic drugs, it is important to establish plans for changing the policy 
of medical care institutes, which are amongst the bottom 20% of introduction rate, 
where a policy maker does not shift to generic drugs even in the area of expensive 
drugs such as anti anticancer agents and radio contrast agents.
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objeCtives: Health Transformation Program(HTP) started in year 2003 by MoH of 
Turkey. All health system changed dramatically. It had impact on all health con-
sumptions and expenditures. The aim of this study is to show the impact of HTP 
on the imported pharmaceuticals(IP) and local manufactured pharmaceutical(LMS) 
sales in Turkey. Methods: Pharmaceutical retail sales data in units and 
volume(US$) from year 1998 to 2012 were retrieved from IMS Dataview. Local and 
import consumption trends were reviewed. The data was analyzed with Microsoft 
Excel 2010. Results: Total unit sales were 689M in 1998, 698M in 2002 and 1768 M 
in 2012; after 10 years of HTP. Total sales were 1937M, 2526M and 8000 M USD for 
the same years, respectively. Between 1998 and 2012, CAGR(Cumulative Annual 
Growth Rate) of unit sales was 7%, while the majority of this growth came from 
HTP(9,7% after HTP vs 0,3% before HTP). There was no significant change in unit 
sales between 1998 and 2002; total CAGR was 0,3%. Sales between 1998 and 2012 in 
USD had an average growth rate of 10,7%. Comparing CAGR for before and after HTP; 
LMP was 1,5% before and 7% after while IP showed an inverse ratio with the total 
and LMP values and was 23,5% and 13,1% before and after. In the beginning of the 
15 years period market share for local manufacturing 92,6% in units and 80,8% in 
USD; in 2002 dropped down to 88,8% in units and 65,7% in USD, and finally in 2012 to 
75,2% in units and 49,8% in USD. ConClusions: The percentage of IP both in units 
and volume increased in years. This increase may be caused by different reasons, 
particularly new oncology and biotechnology molecules. It was observed that the 
volume increase in IP or decrease in LMP was limited by the HTP.
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objeCtives: To analyse the current requirements and patterns for drug use moni-
toring in Europe and highlight new ways for pharmaceutical companies to meet 
these requirements Methods: We combined three methods of data collection to 
characterise current requirements and patterns for drug use monitoring: 1) review of 
official reports by European agencies; 2) analysis of data elements on the European 
Medicines Agency (EMA) website; and 3) interviews with experts from pharma-
ceutical companies, facing requirements for conducting drug utilisation studies 
(DUS). Results: The recent Good Vigilance Practice (GVP) established a clear regula-
tory framework for drug safety monitoring and calls for the assessment of the effec-
tiveness of risk minimisation measures (RMMs). This should include the evaluation 
of their implementation and outcome. DUS provide simple metrics for monitoring 
of appropriate drug use, and thus the implementation of RMMs. We identified 28 
drugs with DUS in their risk management plan and an additional 23 DUS requested 
by EMA. We observed a top total number of requests for DUS in the fields of contra-
ception (n= 10), infectious diseases (mainly HIV and hepatitis) (n= 8) and diseases 
of the metabolism (mainly diabetes) (n= 6) and less for other therapeutic areas. The 
main reasons for DUS requests were monitoring of off-label use (n= 30) and new 
safety concerns (n= 27). Experts confirmed an increasing demand for DUS. In order 
to optimise the RMMs, repetitive DUS in different points in time are necessary. This 
study analyses DUS’ critical data elements allowing for the automation of such 
measurements. ConClusions: Current and future EMA practice for DUS seems 
to focus on new active substances, particularly in diseases of high public health 
relevance and infectious diseases. To meet this demand, pharmaceutical compa-
nies are required to propose more repetitive measurements of the drug use. This 
study identifies data elements allowing for the automation of such measurements.
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objeCtives: The medicines bill in high income countries accounts for approxi-
mately 17% of total health care expenditure. However, around $500 million could 
be saved a year worldwide by optimising medicines use. This study aims to scope 
the evidence on the effectiveness and cost-effectiveness of interventions to 
address suboptimal use of medicines and pinpoint the evidence gaps to prioritise 
future research. Methods: Systematic searches (up to February 2013) of the NHS 
Economic Evaluation Database, the Cochrane Database of Systematic Reviews and 
the Database of Abstracts of Reviews of Effects for systematic reviews on effec-
tiveness or cost-effectiveness and for primary research on cost-effectiveness of 
interventions. Studies in English set in any country were included. Results: Of 
